Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Authors: Chari, Ajai ^{a, *}, Touzeau, Cyrille ^b, Schinke, Carolina ^c, Minnema, Monique C ^d, Berdeja, Jesus G ^e, Oriol, Albert ^f, van de Donk, Niels W C J ^g, Rodríguez-Otero, Paula ^h, Morillo, Daniel ⁱ, Martinez-Chamorro, Carmen ^j, Mateos, María-Victoria ^k, Costa, Luciano J ^l, Caers, Jo ^m, Rasche, Leo ⁿ, Krishnan, Amrita ^o, Ye, Jing Christine ^p, Karlin, Lionel ^q, Lipe, Brea ^r, Vishwamitra, Deeksha ^s, Skerget, Sheri ^s, Verona, Raluca ^s, Ma, Xuewen ^s, Qin, Xiang ^s, Ludlage, Hein ^t, Campagna, Michela ^u, Masterson, Tara ^s, Hilder, Brandi ^s, Tolbert, Jaszianne ^s, Renaud, Thomas ^v, Goldberg, Jenna D ^v, Kane, Colleen ^s, Heuck, Christoph ^s, San-Miguel, Jesus ^h, Moreau, Philippe ^b

Source: In The Lancet Haematology April 2025 12(4):e269-e281

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Authors: Ye, Jing Christine ^{1, ⁎}, Biran, Noa ², Nair, Sandhya ³, Lin, Xiwu ⁴, Qi, Keqin ⁵, Londhe, Anil ⁵, Ammann, Eric ⁶, Renaud, Thomas ⁷, Kane, Colleen ⁸, Parekh, Trilok ⁹, Gray, Kathleen ⁸, Peterson, Steve ¹⁰, Costa, Luciano J. ¹¹

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2025 25(2):124-134

Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab

Authors: Chari, Ajai, Krishnan, Amrita, Rasche, Leo, Ye, Jing Christine, Garfall, Alfred, Popat, Rakesh, Lipe, Brea, Qin, Xiang, Campagna, Michela, Masterson, Tara, Tomlinson, Chalmer, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Smit, M. Damiette, Gray, Kathleen, Kane, Colleen, Heuck, Christoph, van de Donk, Niels W.C.J.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2024 24(10):665-693

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Authors: Jing Christine Ye, Biran, Noa, Nair, Sandhya, Xiwu Lin, Keqin Qi, Londhe, Anil, Ammann, Eric, Renaud, Thomas, Kane, Colleen, Parekh, Trilok, Gray, Kathleen, Peterson, Steve, Costa, Luciano J.

Source: Clinical Lymphoma, Myeloma & Leukemia; Feb2025, Vol. 25 Issue 2, p124-134.e5, 16p

Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model

Authors: Willemin, Marie-Emilie, Gong, Jue, Hilder, Brandi W., Masterson, Tara, Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, De Zwart, Loeckie, Girgis, Suzette, Ma, Xuewen, Ouellet, Daniele

Source: Targeted Oncology; Nov2024, Vol. 19 Issue 6, p965-979, 15p

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

Authors: Rodriguez-Otero, Paula, van de Donk, Niels W. C. J., Pillarisetti, Kodandaram, Cornax, Ingrid, Vishwamitra, Deeksha, Gray, Kathleen, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Masterson, Tara, Heuck, Christoph, Kane, Colleen, Verona, Raluca, Moreau, Philippe, Bahlis, Nizar, Chari, Ajai

Source: Blood Cancer Journal; 3/7/2024, Vol. 14 Issue 1, p1-13, 13p

Subject Terms: MULTIPLE myeloma, BISPECIFIC antibodies, G protein coupled receptors, CHIMERIC antigen receptors, PATIENT experience

IL-33 is more potent than IL-25 in provoking IL-13–producing nuocytes (type 2 innate lymphoid cells) and airway contraction

Authors: Barlow, Jillian L., Peel, Samantha, Fox, Jane, Panova, Veera, Hardman, Clare S., Camelo, Ana, Bucks, Christine, Wu, Xiaoying, Kane, Colleen M., Neill, Daniel R., Flynn, Robin J., Sayers, Ian, Hall, Ian P., McKenzie, Andrew N.J.

Source: In The Journal of Allergy and Clinical Immunology October 2013 132(4):933-941

MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: Rasche, Leo, Schinke, Carolina, Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, María-Victoria, Christine Ye, Jing, Vishwamitra, Deeksha, Singh, Indrajeet, Qin, Xiang, Campagna, Michela, Masterson, Tara, Hilder, Brandi W., Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, Chari, Ajai

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S561-S562

Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: Rasche, Leo, Schinke, Carolina, Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, María-Victoria, Christine Ye, Jing, Vishwamitra, Deeksha, Singh, Indrajeet, Qin, Xiang, Campagna, Michela, Masterson, Tara, Hilder, Brandi W., Tolbert, Jaszianne, Renaud, Thomas, Heuck, Christoph, Kane, Colleen, Chari, Ajai

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S240-S240

HAUTE HORLOGERIE.

Authors: Kane, Colleen (AUTHOR)

Source: Fortune. 11/1/2015, Vol. 172 Issue 6, p57-60. 3p. 6 Color Photographs.

Subject Terms: Men's wrist watches, Clocks & watches

Company/Entity: Patek Philippe SA , Montres Breguet SA , Hublot SA

Humanized IL-25 antibodies

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Authors: Pillai, Rathi N., Ramalingam, Suresh S., Thayu, Meena, Lorenzini, Patricia, Alvarez Arias, Diana A., Moy, Christopher, Hutnick, Natalie, Knoblauch, Roland, Feng, Huaibao, Kane, Colleen, Horn, Leora, Reck, Martin, Ponce, Santiago

Source: In JTO Clinical and Research Reports February 2021 2(2)

Humanized IL-25 Antibodies

P-328 Talquetamab vs real-world physician's choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/ refractory multiple myeloma (RRMM)

Authors: Ye, Jing Christine, Biran, Noa, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Ammann, Eric, Renaud, Thomas, Kane, Colleen, Parekh, Trilok, Gray, Kathleen, Peterson, Steve, Costa, Luciano

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S219-S220

MxiE Regulates Intracellular Expression of Factors Secreted by the Shigella flexneri 2a Type III Secretion System.

Authors: Kane, Colleen D., Schuch, Raymond, Day, William A. jr

Source: Journal of Bacteriology; August 2002, Vol. 184 Issue 16, p4409-4419, 11p

Regional conductance changes during hemorrhage in pregnant and nonpregnant conscious rabbits.

Authors: Brooks, Virginia L., Kane, Colleen M., Welch, Lisa S.

Source: American Journal of Physiology; September 1999 pt2, Vol. 277 Issue 3, pR675-R681, 7p

Effect of host cell polarization state on the growth of Chlamydia trachomatis in culture

Authors: Kane, Colleen Diane.

Relation: Also available on the Internet.

Access URL: http://hdl.handle.net/2027/wu.89063835730

Altered heart rate baroreflex during pregnancy: role of sympathetic and parasympathetic nervous systems.

Authors: Brooks, Virginia L., Kane, Colleen M., Van Winkle, Donna M.

Source: American Journal of Physiology; September 1997 pt 2, Vol. 273, pR960-R966, 7p

Critical Roles of a Cyclic AMP Responsive Element and an E-box in Regulation of Mouse Renin Gene Expression

Authors: Pan, Li ^{‡, §}, Black, Thomas A. ^{‡, ¶}, Shi, Qi ^‖, Jones, Craig A. ^‡, Petrovic, Nenad ^{‡, **}, Loudon, John ^{‡, ‡}, Kane, Colleen ^‡, Sigmund, Curt D. ^‖, Gross, Kenneth W. ^{‡, §§}

Source: In Journal of Biological Chemistry 7 December 2001 276(49):45530-45538

Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy

Authors: Brooks, Virginia L., Welch, Lisa S., Kane, Colleen M.

Source: In American Journal of Obstetrics and Gynecology February 2001 184(3):476-482